Research suggests that monitoring the concentrations of α‐syn and PARP‐1 in patients' plasma samples could serve as valuable biomarkers, offering a noninvasive approach to diagnosing PD and probably its severity. The gene discussed is PARP1; the disease is Parkinson disease.